Actively Recruiting
M. Avium WGS During Mav-PD Treatment
Led by University Health Network, Toronto · Updated on 2024-05-21
40
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
Sponsors
U
University Health Network, Toronto
Lead Sponsor
W
Western University, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere. The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.
CONDITIONS
Official Title
M. Avium WGS During Mav-PD Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 and older
- Willing to provide informed consent and participate in study procedures
- Residing continuously in Ontario during the past five years
- Diagnosed with Mycobacterium Avium pulmonary disease (Mav-PD), either initial or recurrent
- Meet American Thoracic Society/Infectious Diseases Society of America criteria for Mav-PD
You will not qualify if you...
- No available pre-treatment M. avium isolate in the PHOL isolate bank
- Unable to produce sputum spontaneously or by induction
- Lung cavitation larger than 3 cm in diameter
- Known macrolide-resistant MAC infection
- HIV infection
- Diagnosis of cystic fibrosis
- History of solid organ or blood transplantation
- Severe illness expected to limit survival to less than 24 months
- Living in mid/north York region (King, Aurora, Newmarket, Whitechurch-Stouffville, East Gwillimbury, Georgina)
- Moved between Toronto/southern York region, non-Toronto/York region, or mid-northern York region in past 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Health Network
Toronto, Ontario, Canada, M5G
Actively Recruiting
Research Team
T
Theodore Marras, MD
CONTACT
M
Matty Mehrabi, BSc, M.Ed
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here